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ABSTRACT
The EURO-QOL (EQ-5D), a generic quality of life measure, is a self-report scale. The aim was to study the reliability, validity and 
feasibility of the Turkish version of the EQ-5D as an instrument to evaluate quality of life in lung cancer patients in Turkish society. A 
prospective cohort study carried out within the framework of the multicenter Lung Cancer Association Project which was conducted 
in collaboration with Turkish Thoracic Society, Lung and Pleural Malignancies working group and Health and Quality of Life Society. 
A total of 266 patients were included in the study with a mean age of 61.3 years. 75,9% of the patients had chemotherapy alone; 
9% received sequential chemotherapy and radiotherapy, 8,6% were given concurrent chemotherapy and radiotherapy, and 6,4% of 
them received radical radiotherapy alone. EQ-5D score measures at the moment of diagnosis were found to be moderately reliable 
while measures at the 3rd chemotherapy cycle, 5th chemotherapy cycle and after the radiotherapy were highly reliable. The items of 
the EQ-5D were found to be consistent among themselves. EQ-5D Visual Analogue Scale scores at diagnosis, the 3rd cycle, the 5th 
cycle and following radiotherapy were assessed to be correlated with each other. EQ-5D scale was found to be valid as it meets the 
conditions of 6 fit indices in our study design. The psychometric properties of the Turkish version of the EQ-5D questionnaire is a valid 
and reliable scale for patients with lung cancer in Turkey and it can be safely used in clinical practices.
Keywords: Lung cancer, Quality of life, EQ-5D, EQ-5D Visual Analogue Scale, Validity
ÖZET
Akciğer Kanserli Hastalarda İzlem Sürecindeki Değişikliklerin Yaşam Kalitesine Etkisinin EQ-5D Ölçeği ve Takip Sonuçları 
ile Değerlendirilmesi (AKAYAK-1 Çok Merkezli Proje)
EURO-QOL (EQ-5D) genel yaşam kalitesi ölçeği bir öz-bildirim ölçeğidir. Amaç Türk toplumunda akciğer kanserinde yaşam kalitesi 
değerlendirme aracı olarak EQ-5D’nin Türkçe sürümünün güvenilir, geçerli ve uygulanabilir olup olmadığının araştırılmasıdır. Türk Toraks 
Derneği, Akciğer ve Plevra Maligniteleri Çalışma Grubu ile Sağlıkta Yaşam Kalitesi Derneğinin ortaklaşa yürüttüğü çok merkezli Akciğer 
Kanserinde Yaşam Kalitesi Projesi çerçevesinde yürütülen prospektif bir kohort çalışmasıdır. Çalışmaya yaş ortalaması 61.3 yıl olan 
266 hasta alındı. Hastaların %75,9’u sadece kemoterapi; %9’u ardışık kemoterapi ve radyoterapi, %8,6’sı eşzamanlı kemoterapi ve 
radyoterapi, %6,4’ü sadece radikal radyoterapi almıştır. Tanı anındaki EQ-5D indeks skor ölçümünün orta derecede güvenilir, 3. ke-
moterapi küründeki ölçüm, 5. kemoterapi küründeki ölçüm ve radyoterapi sonrasındaki ölçümlerin yüksek derecede güvenilir olduğu 
bulunmuştur. EQ-5D maddelerinin kendi içinde tutarlı olduğu görülmüştür. 
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INTRODUCTION
Quality of life (QOL) is a broad concept that as 
affected by the individual’s physical health, psy-
chological state, beliefs, social relations and rela-
tions with the environment in a complicated way. 
It is a significant measure for the evaluation of the 
state of health and the effects of treatments. Health 
related quality of life is associated with how the 
individual perceives the disease and the functional 
effects of treatments given.1-4
In the assessment of the treatments given, response 
rate or the length of survival is not a criterion alone 
in lung cancer. The purpose of the treatment is to 
attain improvement in life quality and a prolonged 
survival with the palliation of symptoms. Ques-
tioning the quality of life is a significant measure 
in evaluating the palliative effect of treatment or 
treatment-associated problems and deciding on the 
clinical course.5,6
Euro QoL (EQ-5D) quality of life scale was de-
veloped by the Euro Qol group in 1987 and was 
translated into more than 60 languages. It is a self-
report scale which evaluates five dimensions with 
five questions. The questionnaire consists of two 
sections.
EQ-5D index scale; consist of five dimensions 
namely; mobility, self-care, usual activities, pain/ 
discomfort and anxiety/depression. Each item on 
the scale is assessed on three levels (Likert type). 
As well as obtaining response distributions of these 
dimensions; health availability index scores can 
be calculated.  Responses at each dimension have 
three options: no problems, some problems and 
major problems. The scale defines 243 possible 
different health problems. Over the 5 dimensions 
of the scale, index scores are calculated varying be-
tween -0.59 and 1. In the score function, 0 refers to 
death, 1 refers to perfect health while negative val-
ues show such conditions as unconsciousness and 
bedridden living etc. For the calculation of scores, 
index score was calculated using the coefficients 
produced by Dolan et al. in their study.7,8
EQ-5D Visual Analogue Scale (VAS); includes the 
individuals’ responding about their current state of 
health by referring to a point between 0 and 100, 
that is ‘the worst imaginable health state’ and ‘the 
best imaginable health state’. It is a thermometer-
like visual analogue scale.7,8
The aim of the present study is to analyze the reli-
ability, validity and feasibility of the Turkish ver-
sion of the EQ-5D generic quality of life scale as 
an instrument to evaluate quality of life in lung 
cancer patients in Turkish society.
PATIENTS AND METHODS
Scope 
The present study was carried out within the frame-
work of the AKAYAK (Quality of Life in Lung 
Cancer) Project conducted in collaboration of 
Turkish Thoracic Society and Turkish Society for 
Quality of Life Research (SAYKAD). AKAYAK 
project aimed to reveal the psychometric features 
(validity and reliability) of the Turkish versions of 
life quality assessment scales that are developed 
specifically for lung cancer and are commonly used 
in lung cancer patients in the world and to show 
clinical performances of these scales and their sen-
sitivity to changes. It was intended to evaluate the 
effect of the changes during the follow-up period 
on the life quality of lung cancer patients observed 
with EQ-5D scale and follow-up results in five dif-
ferent health centers across Turkey and to inves-
tigate whether the Turkish version of the EQ-5D 
scale is reliable, valid and feasible as a life quality 
assessment instrument in lung cancer among Turk-
ish society. 
Approval was obtained from the Ege University 
Research Ethics Committee within the scope of the 
AKAYAK project. All the patients were included 
EQ-5D Vizuel Analog Skalası tanı anında, 3. kürde, 5. kürde ve radyoterapi sonrası değerlendirildiğinde birbiri ile korele bulunmuştur. 
Çalışma modelimizde 6 tane uyum indeksi koşulları yerine getirdiğinden EQ-5D ölçeği geçerli bulunmuştur. EQ-5D genel yaşam kalitesi 
ölçeğinin Türkçe sürümünün psikometrik özellikleri, Türkiye’deki akciğer kanserli hastalarda geçerli ve güvenilir bir ölçektir ve klinik 
pratikte güvenle kullanılabilir.
Anahtar Kelimeler: Akciğer kanseri, Yaşam kalitesi, EQ-5D, EQ-5D Vizuel Analog Skalası, Geçerlilik
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in the study after reading, understanding and sign-
ing the written consent form.
Inclusion Criteria for the Study
- Stage IIIB or IV cases (including all histological 
types) diagnosed with primary lung cancer 
- Cases that received no previous treatment and are 
planned to be given chemotherapy (CT), chemora-
diotherapy (CRT) or radiotherapy (RT)
- Cases who were literate, could read and fill in the 
test forms and accepted to participate in the study 
and to come for examinations 
- Cases who signed the written consent form for 
voluntary participation 
Study Type and Design
The present study is a prospective cohort (obser-
vational) study. We contacted 299 LC patients 
undergoing active treatment from April 2010 to 
January 2013 in an inpatient setting or at the out-
patient clinics of five comprehensive cancer cen-
tres in western Turkey. Study data were collected 
using two questionnaire batteries consisting of the 
personal disease information form and the EQ-5D 
generic quality of life form. Patients who accepted 
to participate in the study and who signed the con-
sent form were included in the evaluations. The 
personal disease information form was filled in by 
the researcher on the first visit upon the diagnosis. 
Later, the EQ-5D questionnaire was filled in by the 
patient prior to the doctor’s examination, following 
a detailed explanation in an empty and quiet room. 
The scale was later responded prior to the 3rd and 
5th chemotherapy cycle by the patients receiving 
CT and prior to treatment and 3 weeks after the 
completion of treatment by those given CRT or RT. 
This timing was defined according to the period of 
treatment assessment. ECOG (Eastern Cooperative 
Oncology Group) scores and Karnofsky perfor-
mance status were recorded by the doctor during 
the same visits. 
Staging of all the patients with lung cancer was 
done in accordance with the TNM (Tumor, lymph 
node, metastasis) classification. Treatments of pa-
tients were planned according to their phases and 
performance status. Accordingly, patients were 
given CT alone, or simultaneous/consecutive CRT 
or radical RT. Palliative RT was applied when nec-
essary. In patients with a serum creatinine level of 
>1.5 mg/dl, CT was recommended in combination 
with carboplatin instead of cisplatin.
Follow-up and Response Evaluation
The patients were included in follow-ups in terms 
of treatment, response to treatment, toxicity and 
survival. Treatments given to the patient and the 
course were recorded. Treatment response was 
completed according to the Response Evaluation 
Criteria in Solid Tumors (RECIST) by the re-
searcher, and toxicity information was completed 
according to the Common Terminology Criteria for 
Adverse Effects (CTCAE). CT related side effects 
were recorded after each cycle. In response evalua-
tion, both cycles were given following the CT and 
one month after the RT.  
Statistical Analysis
The data of the study were analyzed using the Sta-
tistical Package for the Social Sciences (SPSS) 19 
and Medcalc 9 (Mariakerke, Belgium) programs. 
Quantitative data were tested for normal distribu-
tion with Kolmogorov test; variables showing nor-
mal distribution were analyzed using parametric 
methods while those following a non-normal dis-
tribution were analyzed with nonparametric test 
models.  Independent two groups were compared 
using independent t test and Mann Whitney U test. 
Multiple independent groups were compared with 
each other using Kruskal-Wallis H test and Oneway 
Anova, and for the differences between groups, 
Bonferonni corrected Mann Whitney U and LSD 
were employed. Dependent two groups were com-
pared with paired T test and repeated measures 
Anova tests were used for the comparison of multi-
ple dependent groups. Kendall Tau-b test was used 
to study the correlations between quantitative data. 
For the comparison of the categorical data, pearson 
chi-square, chi-square, Fisher exact and Continu-
ity Correction tests were employed. Kaplan-meier 
(product limit method) analysis was done to ex-
amine the effects of the factors on mortality and 
survival times. In order to measure the effects of 
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prognostic variables on the survival time, Cox Re-
gression analysis was employed. Cut-off values 
were calculated using ROC (Receiver Operating 
Curve) curve analysis. Logistic regression test was 
conducted to determine the cause-effect relations 
of the nominal response variable with the explana-
tory variables at dichotomous and multinominal 
categories. 
A “Confirmatory approach” was used in the reli-
ability and validity analyses in the study. In other 
words, the appropriateness of the questionnaire’s 
construct in its original language was questioned 
in its Turkish version, and no change in the con-
struct of the questionnaire was allowed. Reliability 
analysis was carried out through internal consist-
ency and item analysis approaches. Internal con-
sistency was shown with a Cronbach Alfa value. 
Cronbach Alpha coefficient is between 0 and 1, 
reliability increases as it approaches 1, decreases 
as it approaches 0. If it is < 0.40, the scale is not 
reliable; 0.40-0.60 shows low reliability; 0.60-0.80 
shows moderate reliability, > 0.80 refers to high 
reliability.
Quantitative data are presented in mean±standard 
deviation and median±IQR (Inter quartile range), 
while categorical data are given in numbers (n) and 
percentages (%). The data were examined at a reli-
ability level of 95%, and a p value of over 0.05 was 
accepted as insignificant, while one under 0.05 was 
taken as significant.
RESULTS
After exclusion of incomplete data, a total of 266 
patients diagnosed with lung cancer were evaluat-
ed (Table 1). There was no asymptomatic patient at 
the time of diagnosis. Lung cancer specific features 
and performance score were presented on Table 2. 
The median ECOG (1,00) and Karnofsky perfor-
mance score (90,00) were similar according to the 
tumor cell type (Mann Whitney U Test, p> 0.05), 
except a better ECOG score in small cell lung can-
cer (SCLC) (p= 0.027).
EQ-5D and EQ-5D VAS scores did not vary by 
gender, marital status, occupation, smoking sta-
tus and educational background. In patients with 
accompanying diseases, EQ-5D and EQ-5D VAS 
scores were low. EQ-5D score was lower as the 
age was older (Table 3). EQ-5D was not associ-
ated with the tumor stage and tumor cell type. EQ-
5D VAS score did not vary by tumor cell type and 
stage (Table 4).
EQ-5D score was higher at the time of diagnosis 
and was similar in SCLC and non-small cell lung 
cancer (NSCLC). There was an increase in the EQ-
Table 1. General parameters of lung cancer patients
Parameters n %
Mean Age (years) 61.35±9.57 (35-86) 
Gender
 Male 248 93.2
 Female 18 6.8
Education
 Primary School 188 70.7
 Secondary School 18 6.8
 High School 27 10.1
 University 13 4.9
 None 20 7.5
Marital Status
 Single 7 2.6
 Married 233 87.6
 Divorced 8 3.0
 Widowed 18 6.8
Occupation
 Freelance 72 27.1
 Wage-earner 15 5.6
 Retired 160 60.2
 Unemployed 19 7.1
Smoking Status
 Never smoked 13 4.9
 Smoker 52 19.5
 Gave up 201 75.6
Comorbidity
 Yes 94 35.3
 Hypertension  27 24.5
 COPD   23 20.9
 Coronary artery disease 23 20.9
 Diabetes mellitus 22 20.0
 Solid organ tumor 5 4.5
 Chronic kidney failure 3 2.7
 Peripheral artery disease 2 1.8
 Gastric ulcer 2 1.8
 Hepatitis B  2 1.8
 Hyperthyroidism 1 0.9
 No 172
COPD= Chronic obstructive lung disease 
5UHOD   Number: 1   Volume: 28   Year: 2018
International Journal of Hematology and Oncology
5D and EQ-5D VAS scores of SCLC patients while 
a change in the form of a decrease was present in 
NSCLC patients (EQ-5D Index score change, p= 
0.036) (EQ-5D VAS change, p= 0.049). The fi-
nal EQ-5D and EQ-5D VAS scores of SCLC pa-
tients are higher than those of NSCLC patients. 
In responses given at diagnosis to each item; no / 
some / major problems were present for mobility 
(62.8%, 30.5%, 6.8%), self care (81.2%, 16.2%, 
2.6%), usual activities (57.1%, 25.6%, 17.3%), 
pain / discomfort (43.6%, 45.9, 10.5%) and anxi-
ety / depression (67.3%, 29.7%, 3.0%).
When the correlations among the changes in EQ-
5D, EQ-5D VAS, ECOG and Karnofsky scores 
were evaluated; a negative correlation was found 
between difference ECOG and difference Karnof-
sky (high correlation), difference EQ-5D (moder-
ate correlation) and difference EQ-5D VAS (mod-
erate correlation). That is, if difference ECOG had 
a (-) value, difference Karnofsky, difference EQ-
5D and difference EQ-5D VAS had (+) values. 
Difference Karnofsky was found to have a positive 
correlation with difference EQ-5D (high correla-
tion) and difference EQ-5D VAS (moderate corre-
lation). In other words, if difference Karnofsky had 
a (+) value, difference EQ-5D and EQ-5D VAS had 
(+) values as well. 
There was a positive correlation between differ-
ence EQ-5D VAS and difference EQ-5D (high cor-
relation), and if difference EQ-5D VAS had a (+) 
value, difference EQ-5D had a (+) value as well. 
All the correlations among the changes in EQ-5D, 
EQ-5D VAS, ECOG and Karnofsky scores were 
significant (p= 0.000).
When a cut off value for mortality was intended ac-
cording to EQ-5D change and EQ-5D VAS change; 
difference EQ-5D cut-off was -0.79. Sensitivity 
was 75%, specificity was 98.4% and the area un-
der the curve was 0.793±0.091 (p= 0.001). Differ-
ence EQ-5D VAS cut-off was -0.30, with sensitiv-
ity 75%, specificity 84,3% and the area under the 
curve 0.730±0.11 (p= 0.035).
When the effect of EQ-5D and EQ-5D VAS score 
changes on survival according to the cut off value 
specified for mortality was examined (Cox Regres-
sion - Backward Stepwise (Wald) Model), it was 
31,732 times higher in exitus patients with EQ-5D 
change values of [≤-0.79] than surviving patients 
(p= 0.001). It was 4.630 times higher in exitus pa-
tients with EQ-5D VAS change values of [≤ -0.30] 
Table 2. Lung cancer specific parameters
Parameters n %
Tumor cell type
 Squamous 100 37.6
 Adenocarcinoma 64 24.1
 Small cell lung carcinoma 56 21.0
 NSCLC (no subgroups specified)   29 10.9
 Radiologic lung tumor 8 3.0
 Non classified 5 1.9
 Large cell 4 1.5
Tumor stage 
 Stage IIIB 86 22.3
 Stage IV 180 67.7
Location of Metastasis 
 Bone 65 29.8
 Opposite lung 36 16.5
 Adrenal 34 15.6
 Brain 26 11.9
 Liver 25 11.5
 Cervical lymph gland 16 7.3
 Abdominal lymph gland 7 3.2
 Axillary lymph gland 6 2.8
 Skin 2 0.9
 Kidney 1 0.5
Symptoms
 Cough 180 67.7
 Dyspnea 147 55.3
 Weight loss 145 54.7
 Loss of appetite 122 45.9
 Localized pain  118 44.4
 Pain in the chest 103 38.7
 Aphonia 55 20.7
 Hemoptysis 54 20.3
 Fever 28 10.5
 Neurologic symptoms 24 9.0
 Vena cava superior 11 4.1
      syndrome
 Horner syndrome 2 0.8
Type of Treatment
 Chemotherapy 202 75.9
 Chemotherapy +  24    9.0
   Radiotherapy (Consecutive)   
 Chemoradiotherapy  23 8.6
      (Simultaneous)
 Radical Radiotherapy 17 6.4 
Treatment Response
 Complete 5 7.1
 Partial 43 61.4
 Stable 9 12.9
 Progression 13 18.6
NSCLC: Non small cell lung cancer 
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in comparison with surviving patients (p= 0.037). 
EQ-5D change was a more significant risk factor 
than EQ-5D VAS change.
When EQ-5D changes were grouped as (-), 0 and 
(+) values and the risk factors affecting change 
were evaluated (logistic regression - enter model); 
tumor cell type, ECOG and Karnofsky perfor-
mance score changes determined the change in 
EQ-5D scores significantly. In NSCLC patients, 
the number of patients with a negative difference 
EQ-5D value was 3.035 times higher than the num-
ber of positive patients. In patients with positive 
difference ECOG values, the number of patients 
with a negative difference EQ-5D value was 3.030 
times higher than the number of positive patients. 
In patients with negative difference Karnofsky 
scores, the number of patients with a negative dif-
ference EQ-5D value was 1.096 times higher than 
the number of positive patients.
When EQ-5D VAS score changes were grouped 
as (-), 0 and (+) values and the risk factors affect-
ing change were evaluated; smoking, ECOG and 
Karnofsky score changes determined the change in 
EQ-5D VAS significantly.
In smokers, the number of patients with a nega-
tive difference EQ-5D VAS value was 4.643 
times higher than the number of positive patients. 
In those with a positive difference ECOG value, 
Table 3. EQ-5D Index Score and Eq-5d Vas Score according to socio-demographic data
    EQ-5D Index Score  p EQ-5D VAS Score p
    Mean SD   Mean SD 
 
Gender Male 0.66 0.36 0.567 66.52 20.68 0.272
 Female 0.71 0.32  63.89 20.40 
Marital Status Single 1.72 1.26 0.07 186.73 65.07 0.14
 Married 0.68 0.34  67.23 20.61 
Occupation Freelance 0.61 0.35 0.226 66.81 20.51 0.251
 Wageworker 0.82 0.31  76.00 18.34 
 Retired 0.66 0.37  65.66 21.22 
 Unemployed 0.68 0.34  62.63 16.61 
Smoking Status Never smoked 0.66 0.35 0.665 63.85 17.70 0.2
 Smoker 1.44 0.61  142.77 35.24 
 Gave up  0.65 0.37  65.07 21.42 
Graduation Primary 0.64 0.36 0.534 66.93 20.41 0.706
 Secondary 0.79 0.22  61.76 19.03 
 High School 0.65 0.40  65.07 25.28 
 University 0.78 0.31  71.15 19.06 
 None 0.64 0.42  63.33 19.10 
Comorbidity Yes 0.60 0.41 0.049 61.85 20.69 0.008
 No 0.69 0.33  68.81 20.24 
Age <40 =A 0.82 0.16 0.049 61.67 29.30 0.007
 [40-49] =B 0.74 0.35  60.71 20.99 
 [50-59] =C 0.71 0.34  71.05 20.26 
 [60-69] =D 0.66 0.34  67.45 19.81 
 >=70 =E 0.54 0.41  59.05 20.23 
    P(B-E)= 0.028* P(C-E)= 0.006   P(B-C)= 0.035  P(C-E)= 0.001
     P(D-E)= 0.015
OVERALL  0.66 0.36   66.34 20.64  
Oneway Anova-Post Hoc Test : LSD     -       independent t test  
SD: Standard deviation; EQ-5D VAS: EQ-5D Visual Analogue Scale; EQ-5D: Euro Quality of Life  Scale 
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the number of patients with a negative difference 
EQ-5D VAS value was 2.336 times higher than 
the number of positive patients. In patients with 
negative difference Karnofsky values, the number 
of patients with a negative difference EQ-5D VAS 
value was 1.074 times higher than the number of 
positive patient difference.
EQ-5D was moderately reliable in the question-
naire at the time of diagnosis while it was highly 
reliable in the questionnaires given at the 3rd cycle, 
5th cycle and following the RT. At diagnosis, the 
3rd cycle, the 5th cycle and following the RT, in 
each item excluded, the new Cronbach alpha value 
did not go up only except anxiety/depression. The 
overall Cronbach alpha was 0.791, 0.838, 0.87 and 
0.943 in first visit, 3rd cycle, 5th cycle and follow-
ing RT. All the items on the scale gave significant 
correlations with their own dimensions. There 
was a significant correlation between EQ-5D VAS 
scores of diagnosis- 3rd cycle, diagnosis-post RT 
and 3rd cycle- 5th cycle (p= 0.000). Since the 
expected and observed correlations between the 
items are in compliance with each other, EQ-5D 
scale was found to be reliable. Confirmatory factor 
analysis was carried out to test validity (Figure 1). 
The 5 items of the scale were tested for compli-
ance with a single factor and this model was devel-
oped for initial values only. In the other repeating 
questionnaires (during the 3rd cycle, during the 5th 
cycle, following RT), the model could not be cal-
culated due to lack of data.  
The comparative fit index (CFI) showed good fit 
0.964 and the normed fit index (NFI) showed ex-
cellent fit 0.954. Chi-square fit index 20.819 was 
not in an acceptable range. The goodness fit index 
(GFI) showed good fit 0.971 and the adjusted good-
ness fit index (AGFI) gave good fit 0.913 as well. 
The root mean square error of approximation (RM-
SEA) was 0.109, which was not in an acceptable 
range. The root mean square error (RMSE) was 
0.015 and showed excellent fit. Akaike Informa-
tion Criterion (CAIC) was desired to be lower than 
the model compared. CAIC was 6.654, which was 
lower than the model of comparison (98.752). In 
general, it was acceptable that at least 3 fit indexes 
meet the conditions in a confirmatory analysis. 
Since 6 fit indexes (CFI, NFI, GFI, AGFI, RMR, 
CAIC) met the required conditions in the study 
model, EQ-5D scale was found to be valid.
Table 4. EQ-5D Index Score and EQ-5D VAS Score distribution according to tumor cell type and tumor phase   
  EQ-5D Index Score p EQ-5D VAS Score p
    Mean SD  Mean SD
Tumor cell type A= Squamous 0.67 0.34 0.189 67.01 20.67 0.049
 B= SCLC 0.73 0.32  70.36 20.02 
 C= Adenocarcinoma 0.62 0.40  67.14 21.00 
 D= Large cell 0.55 0.41  71.25 23.23 
 E= NSCLC(No sub type specified) 0.68 0.37  56.44 18.60 
 F= Non-classified 0.33 0.26  64.00 13.42 
 G= Radiologic lung tumor 0.53 0.38  52.50 20.53 
          P(A-E)= 0.017   P(B-E)= 0.004  
     P(B-G)= 0.021   P(C-E)= 0.023 
Tumor stage A= STAGE IIIB 0.72 0.31 0.07 69.41 21.17 0.021*
 B= STAGE IV 0.61 0.39  63.14 20.21 
          P(A-B)= 0.041
Oneway Anova-Post Hoc Test : LSD        -   independent test  -    
SD: Standard deviation; EQ-5D VAS: EQ-5D Visual Analogue Scale; EQ-5D: Euro Quality of Life  Scale ; SCLC: Small cell lung cancer; NSCLC: Non-
small cell lung cancer
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DISCUSSION
One of the most striking results came up in the 
studies carried out on life quality in lung cancer 
is that the initial quality of life score is the strong-
est and the most independent prognostic factor in 
survival. It is also particularly highlighted that one 
of the finalizing points of treatment studies is the 
quality of life. Symptom palliation must be the ma-
jor priority for these patients who are not expected 
to have an extended survival. ECOG and Karnof-
sky evaluations which are frequently used in this 
field could provide an overall opinion, but quality 
of life measurements is much more comprehensive 
than these evaluations.5
Besides the cancer specific measures such as EO-
RTC QLQ-C30 (European Organization For Re-
search and Treatment of Cancer Quality of Life 
Questionnaire Core 30) and FACIT (the Functional 
Assessment of Chronic Illness Therapy), EQ-5D 
scale is also employed in clinical studies carried 
out in the field of oncology today. EQ-5D is a scale 
which reveals health indirectly and can produce in-
dex based brief scores.9,10
Studies generally report that EQ-5D and EQ-5D 
VAS scores are directly related with ECOG stag-
es.9 In this respect, we found a similar relation in 
our study. The change in the ECOG and Karnof-
sky scoring following the treatment was found to 
be correlated with the change in the EQ-5D and 
EQ-5D VAS scores after treatment. In lung cancer 
patients with accompanying diseases, EQ-5D and 
EQ-5D VAS score were found to be statistically 
lower, which shows us the presence of a relation-
ship between the EQ-5D scale and accompanying 
diseases.  
In lung cancer patients, besides clinical efficiency, 
health related effects on the quality of life and 
costs are also considered while making decisions 
for treatment. Patients with lung cancer have bad 
prognosis and the 5 year survival rates vary be-
tween 6 and 18%. Treatments given could usually 
bring about additional problems for patients. It is 
stated that the EQ-5D scale accurately reflects the 
quality of life in lung cancer patients who have 
a prolonged survival.11 In our study, while pre-
treatment EQ-5D score decreased statistically after 
treatment, while EQ-5D VAS score did not change. 
It was also observed that EQ-5D and EQ-5D VAS 
score increased after treatment in SCLC patients 
while decreasing in NSCLC patients. The change 
in EQ-5D and EQ-5D VAS scores with treatment 
was found to affect survival at a significant rate. 
In one study examining the use of EQ-5D in 
NSCLC patients in the British society, Doyle et 
al. reported that EQ-5D was not affected by age, 
gender and the overall quality of life scale but that 
it was affected by treatment response and disease 
related symptoms.12 EQ-5D may also be used to 
evaluate the effect of a chemotherapy regimen on 
quality of life of patients.13 In our study, since EQ-
5D and EQ-5D VAS in lung cancer patients over 
70 years were found to be statistically low, a corre-
lation was revealed between these scales and age. 
EQ-5D change was found to have no correlation 
with age, gender, smoking, tumor stage, treatment 
type, accompanying diseases and treatment re-
sponse. However, cell type, ECOG and Karnofsky 
score change affected EQ-5D score significantly. It 
was determined that EQ-5D VAS score change was 
affected by smoking, ECOG and Karnosfky score 
change while other factors had no effect.
According to the evaluation by tumor cell type 
and tumor stage, EQ-5D VAS score varied sig-
nificantly. The further the stage was, the lower the 
EQ-5D VAS score got. On the other hand, EQ-5D 
score showed no significant difference by tumor 
cell type and tumor stage. It was seen that EQ-5D 
and EQ-5D VAS score did not differ significantly 
	  
Figure 1. Confirmatory Factor Analysis for the EQ-5D Generic 
Quality of Life Scale
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following the treatment in patients with adenocar-
cinoma while significantly decreasing in squamous 
cell carcinoma. In a study carried out with 95 pa-
tients with NSCLC, the presence of metastasis was 
reported as a factor which apparently affects EQ-
5D and EQ-5D VAS measures. Both were found 
to be low in patients with metastasis.14 In a series 
of 263 patients; HRQOL, as measured by the EQ-
5D domains, and utility were lower in patients with 
progressive disease when compared with progres-
sion free patients. There was a substantial impact 
of lung cancer on patients’ HRQOL, with stage IV 
disease, line of treatment, and progressive disease, 
resulting in considerable deterioration of utility.15 
Analyzing patients according to their stages in our 
study, it was found that EQ-5D and EQ-5D VAS 
values in stage IV patients were significantly lower 
in comparison with other stages. 
EQ-5D measure at diagnosis was found to be mod-
erately reliable, while the measure at the 3rd CT 
cycle, the one at the 5th CT cycle and those after 
the RT were highly reliable. In the evaluation of 
the sub-dimensions of EQ-5D according to inter-
nal consistency analysis, the items were found to 
be self-consistent. The results of the evaluations 
of EQ-5D VAS at diagnosis, the 3rd cycle, the 5th 
cycle and following the RT were found to be cor-
related with each other. Moreover, as our study de-
sign meets the requirements of 6 fit indices, EQ-5D 
was found to be valid.
Limitations included, the absance of quality of life 
assessment in the follow period (progression etc.). 
Since no study has been carried out on the reli-
ability, validity and internal consistency analyses 
of EQ-5D and EQ-5D VAS scales in patients with 
lung cancer in Turkey, our study is the first study to 
carry out these analyses. As the patients included 
in the study were gathered from 5 medical centers 
that frequently accept lung cancer patients, it has a 
large patient population. EQ-5D and EQ-5D VAS 
score are correlated with ECOG and Karnofsky 
performance measures, they reflect the patient’s 
quality of life after treatment accurately and are 
useful in revealing survival. 
In conclusion, it has been revealed with the pre-
sent study that psychometric features of the Turk-
ish version of the EQ-5D generic quality of life 
questionnaire are reliable and valid for lung cancer 
patients in Turkey and can safely be used in clinics.
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